EUVIMEDEUVIMED entdecken
Zurückgezogene PublikationOpen Access · CC BY 4.0

RETRACTED: Tyrosine Kinase Inhibitors Target B Lymphocytes

Nikki Lyn Esnardo Upfold iD, Pavlo Petakh iD, Aleksandr Kamyshnyi iD, Valentyn Oksenych iD

Biomolecules · 2023

DOI: 10.3390/biom13030438 ↗

Kurz gefasst

Zurückgezogene Publikation in der Zeitschrift Biomolecules, 2023. Verfasst von Nikki Lyn Esnardo Upfold und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune disorders and some types of blood cancer originate when B lymphocytes malfunction. In particular, when B cells produce antibodies recognizing the body’s proteins, it leads to various autoimmune disorders. Additionally, when B cells of various developmental stages transform into cancer cells, it results in blood cancers, including multiple myeloma, lymphoma, and leukemia. Thus, new methods of targeting B cells are required for various patient groups. Here, we used protein kinase inhibitors alectinib, brigatinib, ceritinib, crizotinib, entrectinib, and lorlatinib previously approved as drugs treating anaplastic lymphoma kinase (ALK)-positive lung cancer cells. We hypothesized that the same inhibitors will efficiently target leukocyte tyrosine kinase (LTK)-positive, actively protein-secreting mature B lymphocytes, including plasma cells. We isolated CD19-positive human B cells from the blood of healthy donors and used two alternative methods to stimulate cell maturation toward plasma cells. Using cell proliferation and flow cytometry assays, we found that ceritinib and entrectinib eliminate plasma cells from B cell populations. Alectinib, brigatinib, and crizotinib also inhibited B cell proliferation, while lorlatinib had no or limited effect on B cells. More generally, we concluded that several drugs previously developed to treat ALK-positive malignant cells can be also used to treat LTK-positive B cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAntineoplastic AgentsLung NeoplasmsHumansCrizotinibTyrosine Kinase InhibitorsAnaplastic Lymphoma KinaseReceptor Protein-Tyrosine KinasesProtein Kinase InhibitorsLactams, MacrocyclicB-LymphocytesPyrimidinesSulfonesAminopyridinesLactamsPyrazolesBenzamidesIndazolesOrganophosphorus Compounds

Stichwörter der Autor:innen

ALKB-cellLTKautoimmune diseasedrug repurposingplasma cells

Substanzen

CrizotinibTyrosine Kinase InhibitorsAntineoplastic AgentsAnaplastic Lymphoma KinaseReceptor Protein-Tyrosine KinasesProtein Kinase InhibitorsLactams, MacrocyclicceritinibPyrimidinesSulfones

Autor:innen und Institutionen

  • Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology (NTNU), 7028 Trondheim, Norway.
  • Department of Biochemistry and Pharmacology, Uzhhorod National University, 88000 Uzhhorod, Ukraine.
  • Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.
  • Institute of Clinical Medicine (Klinmed), University of Oslo, 0318 Oslo, Norway.

ORCID-Profile: Nikki Lyn Esnardo Upfold, Pavlo Petakh, Aleksandr Kamyshnyi, Valentyn Oksenych

Zitieren

APA

Upfold, N. L. E., Petakh, P., Kamyshnyi, A., & Oksenych, V. (2023). RETRACTED: Tyrosine Kinase Inhibitors Target B Lymphocytes. Biomolecules. https://doi.org/10.3390/biom13030438

Vancouver

Upfold NLE, Petakh P, Kamyshnyi A, Oksenych V. RETRACTED: Tyrosine Kinase Inhibitors Target B Lymphocytes. Biomolecules. 2023. doi:10.3390/biom13030438

BibTeX
@article{Upfold2023,
  author = {Upfold, Nikki Lyn Esnardo and Petakh, Pavlo and Kamyshnyi, Aleksandr and Oksenych, Valentyn},
  title = {RETRACTED: Tyrosine Kinase Inhibitors Target B Lymphocytes},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13030438}
}
Kostenlos starten →